bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

hooksAmpRedirectArticle

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

paywallTypes

createdDate

publishedDate

sponsorType

urlAlias

moreOnThisArticles

commentCount

authorLocations

authors

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

articleSpeeches

socialHeadline

headline

images

flag

firstTopic

glossary

flattenTypeIds

image

relatedLinks

relatedNewsletters

__typename

sponsor

pdfFiles

seriesReverseOrder

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

readingTime

customTimezone

liveContents

Agence France-Presse

Russia’s Sputnik V coronavirus vaccine is 95 per cent effective according to a second interim analysis of clinical trial data, its developers said on Tuesday.
The two-dose vaccine will be available on international markets for less than US$10 (€8.40) per dose, they said, and will be free for Russian citizens.
It can be stored at between 2 and 8 degrees Celsius, they said, instead of the temperatures below freezing required for some other vaccines.
The calculations of its effectiveness were based on preliminary data obtained 42 days after the first dose, Russia’s health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF) said in a statement.


The statement said that the vaccine had shown 91.4 per cent effectiveness 28 days after the first dose, a figure based on 39 cases.
Forty-two days later, after a second dose, data showed “an efficacy of the vaccine above 95 per cent”.
It did not note the number of coronavirus cases used to make the final calculation, however.
“The second analysis was conducted a week after volunteers got the second dose, meaning that their bodies have partially reacted to both doses,” Gamaleya’s director Alexander Gintsburg said in the statement.
He said the centre expects the efficacy rate to be “even higher” three weeks after the second dose.
AstraZeneca-Oxford vaccine ‘offers up to 90 per cent’ protection in trials
The statement said that 22,000 volunteers had been vaccinated with the first dose and more than 19,000 with both doses.
Overseas trials of the vaccine are also taking place in the United Arab Emirates, Venezuela, Belarus and other countries.


Russia in August became the first country to register a coronavirus vaccine but did so ahead of the large-scale clinical trials that are still under way.
Last month, President Vladimir Putin announced that Russia had registered a second coronavirus vaccine, EpiVacCorona, as a global race heats up in producing an effective vaccine to combat the pandemic, which has now claimed the lives of nearly 1.4 million people.
You will need a ‘Covid-19 passport’ to fly in the future
Putin last week said that Russia had manufacturing agreements in place with China and India and encouraged Brazil and South Africa to also mass produce Russian-made vaccines.
Pharma giants Pfizer and BioNTech announced that their virus vaccine is 95 per cent effective, while US company Moderna said last week early results showed its candidate was 94.5 per cent effective.


Meanwhile, the European Commission has reached a deal with US biotech firm Moderna for the supply of its vaccine candidate, an EU official said on Tuesday.
Last week Moderna said its experimental vaccine was 94.5 per cent effective in preventing Covid-19, based on interim data from a late-stage clinical trial.
In August the Commission, which co-leads talks with vaccine makers on behalf of EU states, said preliminary talks with Moderna had been concluded with the aim of signing a contract for the supply of 80 million doses of its vaccine, with the option of buying another 80 million.
Additional reporting by Reuters


The hidden benefits of common vaccines, including reduced dementia and heart risks

Judge allows lawsuit against RFK Jnr’s Covid-19 vaccine policies to proceed

US vaccine advisers say not all newborns need hepatitis B shot, in win for RFK Jnr

JFK’s granddaughter says she has terminal cancer, criticises cousin RFK Jnr

Coronavirus vaccine

Russia says Sputnik V coronavirus vaccine is 95 per cent effective

A nurse prepares to inoculate a patient with Russia’s coronavirus vaccine during post-registration trials. Photo: AFP

China’s coronavirus vaccines: is Southeast Asia ready to trust them?

A worker checks syringes on the production line at Sinovac Biotech in Beijing, China. Photo: TNS

A box of Sinovac Biotech Ltd. SARS-CoV-2 vaccine in Sao Paulo, Brazil, on Wednesday, Nov. 11, 2020. Brazil reversed its decision to suspend Sinovac coronavirus vaccine trials amid criticism the decision was politicized. Photographer: Jonne Roriz/Bloomberg

Malaysia's Prime Minister Muhyiddin Yassin wearing a protective mask arrives at a mosque for prayers, amid the coronavirus disease (COVID-19) outbreak in Putrajaya, Malaysia August 28, 2020. REUTERS/Lim Huey Teng

epa08764098 An Indonesian officer wearing protective gear injects a visitor during the COVID-19 immunization simulation in Depok, West Java, Indonesia, 22 October 2020. At least 2,200 people volunteers around the country will be receive the COVID-19 disease vaccine at the end of 2020. The Indonesian government will monitor their physical health regularly and if the trial proves to be successful, the government will produce 250 million doses of the vaccine in 2021. EPA-EFE/Bagus Indahono

You will need a ‘Covid-19 passport’ to fly international in the future

A traveller stands in line to check in for a China Southern Airlines flight at Los Angeles International Airport. Photo: Bloomberg

News

World

Russia & Central Asia

Coronavirus

Health & Medicine

Europe


Developers said the vaccine will be available on international markets for less than US$10 per dose and will be free for Russian citizens
Overseas trials of the vaccine are also taking place in the United Arab Emirates, Venezuela, Belarus and other countries



Developers said the vaccine will be available on international markets for less than US$10 per dose and will be free for Russian citizens.
